Gsk (GSK) Equity Ratio (2014 - 2025)

Name: Gsk (GSK) Equity Ratio (2014 - 2025) | Business Quant
Creator: Business Quant

Gsk (GSK) posted Equity Ratio of 0.27 for Q4 2025, up 16.55% on a QoQ basis from 0.23 in Q4 2024, and up 16.55% year-over-year from 0.23 in Q4 2024.

Gsk (GSK) has 10 years of Equity Ratio data on file, last reported at 0.27 in Q4 2025.

In Q4 2025, Equity Ratio rose 16.55% year-over-year to 0.27; the TTM figure through Dec 2025 stood at 0.07 (up 34.58% YoY), while the FY2025 annual figure was 0.27, up 16.55% from the prior year.
Equity Ratio grew to 0.27 in Q4 2025, from 0.23 in the prior quarter.
Across five years, Equity Ratio topped out at 0.27 in Q4 2025 and bottomed at 0.18 in Q4 2022.
A 5-year average of 0.22 and a median of 0.23 in 2023 frame the typical range for Equity Ratio.
Annual changes were most pronounced in 2022 — Equity Ratio dropped 7.42% — and 2023, when it rose 28.37%.
Year by year, Equity Ratio stood at 0.19 in 2021, then retreated by 7.42% to 0.18 in 2022, then rose by 28.37% to 0.23 in 2023, then gained by 1.64% to 0.23 in 2024, then advanced by 16.55% to 0.27 in 2025.
The last three Equity Ratio figures came in at 0.27 (Q4 2025), 0.23 (Q4 2024), and 0.23 (Q4 2023), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Novartis Ag	107,124,802.25 Bn	107,124,802.25 Bn	-	-
2	Eli Lilly	969.00 Bn	963.72 Bn	16.22 Bn	0.27
3	Johnson & Johnson	539.46 Bn	517.41 Bn	15.96 Bn	0.40
4	AbbVie	376.92 Bn	367.57 Bn	10.78 Bn	-0.05
5	Merck	285.00 Bn	279.35 Bn	12.09 Bn	0.36
6	Amgen	177.58 Bn	165.55 Bn	5.87 Bn	0.10
7	Gilead Sciences	163.22 Bn	155.50 Bn	5.52 Bn	0.42
8	Pfizer	145.86 Bn	133.09 Bn	-1.21 Bn	0.43
9	Bristol Myers Squibb	111.90 Bn	101.44 Bn	8.07 Bn	0.23
10	Gsk	88.34 Bn	83.66 Bn	-	0.27

Download Data 🔒